Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
- Author
- SULKOWSKI, Mark1 ; POL, Stanislas2 3 ; WENNING, Larissa8 ; SKLAR, Peter8 ; WAHL, Janice8 ; GREAVES, Wayne; MALLOLAS, Josep4 ; FAINBOIM, Hugo5 ; COOPER, Curtis6 ; SLIM, Jihad7 ; RIVERO, Antonio8 ; MAK, Carmen8 ; THOMPSON, Seth8 ; HOWE, Anita Y. M8
[1] Johns Hopkins University School of Medicine, Baltimore, MD, United States
[2] Université Paris Descartes, Inserm U-1016, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
[3] Hospital Clinic-University of Barcelona, Barcelona, Spain
[4] Muñiz Hospital, Buenos Aires, Argentina
[5] University of Ottawa, Ottawa, Canada
[6] Saint Michael's Medical Center, Newark, NJ, United States
[7] University Hospital Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain
[8] Merck Sharp & Dohme, Whitehouse Station, NJ, United States
P05411 study investigators - Source
Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 597-605, 9 p ; ref : 19 ref
- ISSN
- 1473-3099
- Scientific domain
- General medicine general surgery; Microbiology, infectious diseases
- Publisher
- Lancet Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiviral Bocéprévir Etude comparative Forme pégylée Génotype Homme Hépatite virale C Interféron alpha Ribavirine SIDA Traitement Typage Virus hépatite C Virus immunodéficience humaine Interféron alfa Analogue de nucléoside Exploration microbiologique Flaviviridae Hepacivirus Immunodéficit Immunopathologie Infection Inhibiteur protease Lentivirus Pathologie de l'appareil digestif Pathologie du foie Retroviridae Virose Virus
- Keyword (en)
- Antiviral Boceprevir Comparative study Pegylated form Genotype Human Viral hepatitis C Alpha interferon Ribavirin AIDS Treatment Typing Hepatitis C virus Human immunodeficiency virus Interferon alfa Nucleoside analog Microbiological investigation Flaviviridae Hepacivirus Immune deficiency Immunopathology Infection Protease inhibitor Lentivirus Digestive diseases Hepatic disease Retroviridae Viral disease Virus
- Keyword (es)
- Antiviral Boceprevir Estudio comparativo Forma pegilada Genotipo Hombre Hepatítis virica C Interferón alfa Ribavirina SIDA Tratamiento Tipificación Hepatitis C virus Human immunodeficiency virus Interferón alfa Análogo nucleósido Análisis microbiológico Flaviviridae Hepacivirus Inmunodeficiencia Inmunopatología Infección Inhibidor proteasa Lentivirus Aparato digestivo patología Hígado patología Retroviridae Virosis Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02G Viral hepatitis
- Discipline
- Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27531666
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S1473-3099(13)70149-X 
https://dx.doi.org/10.1016/S1473-3099(13)70149-X
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"597\";s:8:\"\u0000*\u0000epage\";s:3:\"605\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SULKOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"POL, Stanislas\";i:1;s:16:\"WENNING, Larissa\";i:2;s:12:\"SKLAR, Peter\";i:3;s:12:\"WAHL, Janice\";i:4;s:14:\"GREAVES, Wayne\";i:5;s:15:\"MALLOLAS, Josep\";i:6;s:14:\"FAINBOIM, Hugo\";i:7;s:14:\"COOPER, Curtis\";i:8;s:11:\"SLIM, Jihad\";i:9;s:15:\"RIVERO, Antonio\";i:10;s:11:\"MAK, Carmen\";i:11;s:14:\"THOMPSON, Seth\";i:12;s:16:\"HOWE, Anita Y. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"597\";s:8:\"\u0000*\u0000epage\";s:3:\"605\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SULKOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"POL, Stanislas\";i:1;s:16:\"WENNING, Larissa\";i:2;s:12:\"SKLAR, Peter\";i:3;s:12:\"WAHL, Janice\";i:4;s:14:\"GREAVES, Wayne\";i:5;s:15:\"MALLOLAS, Josep\";i:6;s:14:\"FAINBOIM, Hugo\";i:7;s:14:\"COOPER, Curtis\";i:8;s:11:\"SLIM, Jihad\";i:9;s:15:\"RIVERO, Antonio\";i:10;s:11:\"MAK, Carmen\";i:11;s:14:\"THOMPSON, Seth\";i:12;s:16:\"HOWE, Anita Y. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"597\";s:8:\"\u0000*\u0000epage\";s:3:\"605\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SULKOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"POL, Stanislas\";i:1;s:16:\"WENNING, Larissa\";i:2;s:12:\"SKLAR, Peter\";i:3;s:12:\"WAHL, Janice\";i:4;s:14:\"GREAVES, Wayne\";i:5;s:15:\"MALLOLAS, Josep\";i:6;s:14:\"FAINBOIM, Hugo\";i:7;s:14:\"COOPER, Curtis\";i:8;s:11:\"SLIM, Jihad\";i:9;s:15:\"RIVERO, Antonio\";i:10;s:11:\"MAK, Carmen\";i:11;s:14:\"THOMPSON, Seth\";i:12;s:16:\"HOWE, Anita Y. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"597\";s:8:\"\u0000*\u0000epage\";s:3:\"605\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SULKOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"POL, Stanislas\";i:1;s:16:\"WENNING, Larissa\";i:2;s:12:\"SKLAR, Peter\";i:3;s:12:\"WAHL, Janice\";i:4;s:14:\"GREAVES, Wayne\";i:5;s:15:\"MALLOLAS, Josep\";i:6;s:14:\"FAINBOIM, Hugo\";i:7;s:14:\"COOPER, Curtis\";i:8;s:11:\"SLIM, Jihad\";i:9;s:15:\"RIVERO, Antonio\";i:10;s:11:\"MAK, Carmen\";i:11;s:14:\"THOMPSON, Seth\";i:12;s:16:\"HOWE, Anita Y. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(13)70149-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"597\";s:8:\"\u0000*\u0000epage\";s:3:\"605\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SULKOWSKI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"POL, Stanislas\";i:1;s:16:\"WENNING, Larissa\";i:2;s:12:\"SKLAR, Peter\";i:3;s:12:\"WAHL, Janice\";i:4;s:14:\"GREAVES, Wayne\";i:5;s:15:\"MALLOLAS, Josep\";i:6;s:14:\"FAINBOIM, Hugo\";i:7;s:14:\"COOPER, Curtis\";i:8;s:11:\"SLIM, Jihad\";i:9;s:15:\"RIVERO, Antonio\";i:10;s:11:\"MAK, Carmen\";i:11;s:14:\"THOMPSON, Seth\";i:12;s:16:\"HOWE, Anita Y. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:194:\"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
